Treatment of a patient with breast cancer and glucose 6-phosphate dehydrogenase deficiency: A case report

Wei-Pang Chung, Ya Tin Hsu, Ya Ping Chen, Hui-Ping Hsu

Research output: Contribution to journalArticle

Abstract

RATIONALE: Glucose 6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymatic disorder of red blood cells that cause hemolytic anemia. Some anticancer drugs are reported to trigger oxidative stress; however, events of hemolysis are rarely discussed in patients with G6PD deficiency required oncologic treatments. PATIENT CONCERNS: Here we reported a young woman with G6PD deficiency safely undergoing breast cancer treatment. DIAGNOSIS: A 29-year-old patient was diagnosed with advanced cancer of the right breast with tumors positive for hormone receptor and human epidermal growth factor receptor 2. INTERVENTIONS: The patient received chemotherapy with doxorubicin, cyclophosphamide, and docetaxel. During the administration of docetaxel, trastuzumab was concurrently administered and was continued after the completion of docetaxel. The patient underwent adjuvant radiotherapy; meanwhile, tamoxifen was administered as adjuvant endocrine treatment. OUTCOMES: The treatment process was smooth. There was no evidence of hemolytic anemia. Except for hot flushes, the patient lives without remarkable side effects from ongoing or previous treatments. LESSONS: Some patients have both G6PD deficiency and malignancy in a geographic area with relatively high incidence of the enzymatic disorder and certain types of cancer. We suggest that our report can contribute to the concern regarding the safety of patients with G6PD deficiency undergoing cancer treatment.

Original languageEnglish
Pages (from-to)e14987
JournalMedicine
Volume98
Issue number13
DOIs
Publication statusPublished - 2019 Mar 1

Fingerprint

Glucosephosphate Dehydrogenase Deficiency
docetaxel
Breast Neoplasms
Hemolytic Anemia
Therapeutics
N,N-dimethyl-3,3-diphenyl-1-methylallylamine
Neoplasms
Adjuvant Radiotherapy
Tamoxifen
Patient Safety
Hemolysis
Doxorubicin
Cyclophosphamide
glucose-6-phosphate dehydrogenase A-
Oxidative Stress
Erythrocytes
Hormones
Drug Therapy
Incidence
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{45f1204f1f17497bad78151d31daba91,
title = "Treatment of a patient with breast cancer and glucose 6-phosphate dehydrogenase deficiency: A case report",
abstract = "RATIONALE: Glucose 6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymatic disorder of red blood cells that cause hemolytic anemia. Some anticancer drugs are reported to trigger oxidative stress; however, events of hemolysis are rarely discussed in patients with G6PD deficiency required oncologic treatments. PATIENT CONCERNS: Here we reported a young woman with G6PD deficiency safely undergoing breast cancer treatment. DIAGNOSIS: A 29-year-old patient was diagnosed with advanced cancer of the right breast with tumors positive for hormone receptor and human epidermal growth factor receptor 2. INTERVENTIONS: The patient received chemotherapy with doxorubicin, cyclophosphamide, and docetaxel. During the administration of docetaxel, trastuzumab was concurrently administered and was continued after the completion of docetaxel. The patient underwent adjuvant radiotherapy; meanwhile, tamoxifen was administered as adjuvant endocrine treatment. OUTCOMES: The treatment process was smooth. There was no evidence of hemolytic anemia. Except for hot flushes, the patient lives without remarkable side effects from ongoing or previous treatments. LESSONS: Some patients have both G6PD deficiency and malignancy in a geographic area with relatively high incidence of the enzymatic disorder and certain types of cancer. We suggest that our report can contribute to the concern regarding the safety of patients with G6PD deficiency undergoing cancer treatment.",
author = "Wei-Pang Chung and Hsu, {Ya Tin} and Chen, {Ya Ping} and Hui-Ping Hsu",
year = "2019",
month = "3",
day = "1",
doi = "10.1097/MD.0000000000014987",
language = "English",
volume = "98",
pages = "e14987",
journal = "Medicine (United States)",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "13",

}

Treatment of a patient with breast cancer and glucose 6-phosphate dehydrogenase deficiency : A case report. / Chung, Wei-Pang; Hsu, Ya Tin; Chen, Ya Ping; Hsu, Hui-Ping.

In: Medicine, Vol. 98, No. 13, 01.03.2019, p. e14987.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of a patient with breast cancer and glucose 6-phosphate dehydrogenase deficiency

T2 - A case report

AU - Chung, Wei-Pang

AU - Hsu, Ya Tin

AU - Chen, Ya Ping

AU - Hsu, Hui-Ping

PY - 2019/3/1

Y1 - 2019/3/1

N2 - RATIONALE: Glucose 6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymatic disorder of red blood cells that cause hemolytic anemia. Some anticancer drugs are reported to trigger oxidative stress; however, events of hemolysis are rarely discussed in patients with G6PD deficiency required oncologic treatments. PATIENT CONCERNS: Here we reported a young woman with G6PD deficiency safely undergoing breast cancer treatment. DIAGNOSIS: A 29-year-old patient was diagnosed with advanced cancer of the right breast with tumors positive for hormone receptor and human epidermal growth factor receptor 2. INTERVENTIONS: The patient received chemotherapy with doxorubicin, cyclophosphamide, and docetaxel. During the administration of docetaxel, trastuzumab was concurrently administered and was continued after the completion of docetaxel. The patient underwent adjuvant radiotherapy; meanwhile, tamoxifen was administered as adjuvant endocrine treatment. OUTCOMES: The treatment process was smooth. There was no evidence of hemolytic anemia. Except for hot flushes, the patient lives without remarkable side effects from ongoing or previous treatments. LESSONS: Some patients have both G6PD deficiency and malignancy in a geographic area with relatively high incidence of the enzymatic disorder and certain types of cancer. We suggest that our report can contribute to the concern regarding the safety of patients with G6PD deficiency undergoing cancer treatment.

AB - RATIONALE: Glucose 6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymatic disorder of red blood cells that cause hemolytic anemia. Some anticancer drugs are reported to trigger oxidative stress; however, events of hemolysis are rarely discussed in patients with G6PD deficiency required oncologic treatments. PATIENT CONCERNS: Here we reported a young woman with G6PD deficiency safely undergoing breast cancer treatment. DIAGNOSIS: A 29-year-old patient was diagnosed with advanced cancer of the right breast with tumors positive for hormone receptor and human epidermal growth factor receptor 2. INTERVENTIONS: The patient received chemotherapy with doxorubicin, cyclophosphamide, and docetaxel. During the administration of docetaxel, trastuzumab was concurrently administered and was continued after the completion of docetaxel. The patient underwent adjuvant radiotherapy; meanwhile, tamoxifen was administered as adjuvant endocrine treatment. OUTCOMES: The treatment process was smooth. There was no evidence of hemolytic anemia. Except for hot flushes, the patient lives without remarkable side effects from ongoing or previous treatments. LESSONS: Some patients have both G6PD deficiency and malignancy in a geographic area with relatively high incidence of the enzymatic disorder and certain types of cancer. We suggest that our report can contribute to the concern regarding the safety of patients with G6PD deficiency undergoing cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=85064107210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064107210&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000014987

DO - 10.1097/MD.0000000000014987

M3 - Article

C2 - 30921210

AN - SCOPUS:85064107210

VL - 98

SP - e14987

JO - Medicine (United States)

JF - Medicine (United States)

SN - 0025-7974

IS - 13

ER -